Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Aiforia Technologies

1.84 EUR

-0.27 %

2,150 following
Corporate customer

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

-0.27 %
-19.16 %
-26.31 %
-28.60 %
-43.54 %
-48.60 %
-55.57 %
-
-63.74 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
61.82M EUR
Turnover
43.85K EUR
P/E (adj.) (25e)
EV/EBIT (adj.) (25e)
P/B (25e)
EV/S (25e)
Dividend yield-% (25e)
Coverage
Recommendation
Accumulate
Target price
Updated
19.11.2025
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 19.11.2025

Latest extensive report

Released: 24.04.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6.3.
2026

Annual report '25

2.4.
2026

General meeting '26

28.8.
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
Greetings to the thread, Regarding company coverage, we have some news: we are transferring the primary coverage responsibility for Aiforia mainly to me. Antti L will continue to work with Aiforia as a supporting analyst. I am probably more or less familiar to most readers, but for...
2/16/2026, 2:50 PM
by Antti Siltanen
61
I now have a full, good-sized position in Aiforia. At least I interpret this latest -15% as a completely extra “Faron discount.” The stock was already at my buy price even before this. It seems quite promising to me. Many contracts have already been signed, and there’s no reason ...
2/12/2026, 3:24 PM
by JusaVaan
23
Quoting the message rather than responding to it. Now that Aiforia has taken a real beating on the stock market and the valuation has dropped to 66 million, I hope it won’t be bought out on the cheap now. $81m was paid for Paige, and it is clearly behind Aiforia, at least in terms...
2/12/2026, 11:38 AM
by Jekkku
22
Answering my own question: The volume at Fimlab was approx. 1,600 slides in September 2025 and 3,500 in October, and the number is growing. Price per slide taken from the comprehensive report And with a good margin Fimlab is, however, on the smaller end of the won tenders, so you...
2/12/2026, 7:53 AM
by Jekkku
22
Well, welcome back to a semi-familiar environment then. I tried to pass a question to Luiro for Jukka’s interview regarding Aiforia’s newest model, i.e., gastric cancer: how they see its volumes and whether they have discussed with pathologists and gastroscopists (i.e., surgeons ...
2/16/2026, 3:18 PM
by Vino Pino
9
Yes, that’s right, so there was a comment regarding the share issue back in December here: Aiforia keräsi suunnatulla osakeannilla 4,2 miljoonaa euroa - Inderes
2/19/2026, 12:18 PM
by Antti Siltanen
4
I’ve been checking the Siemens Healthineers website to see if there are any mentions. It seems like there are big medical events happening right now, with more to come. AI and imaging are being trumpeted everywhere. I have strong faith that some of this will benefit Aiforia too, ...
2/12/2026, 6:46 AM
by Salvelinus
3
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.